Economic Evaluation of Ticagrelor for Secondary Prevention Following Acute Coronary Syndromes

• Autor(a) principal: Gouveia, M
• Data de Publicação: 2015
• Outros Autores: Borges, M, Trindade, R, Rikner, K
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.17/2008
• topic: CHLC FAR; Acute Coronary Syndrome/drug therapy; Acute Coronary Syndrome/economics; Adenosine/analogs & derivatives; Adenosine/economics; Adenosine/therapeutic use; Clinical Trials as Topic; Purinergic P2Y Receptor Antagonists/economics; Purinergic P2Y Receptor Antagonists/therapeutic use; Secondary Prevention

INTRODUCTION AND OBJECTIVES: To estimate the cost-effectiveness and cost-utility of ticagrelor in the treatment of patients with acute coronary syndromes (unstable angina or myocardial infarction with or without ST-segment elevation), including patients treated medically and those undergoing percutaneous coronary intervention or coronary artery bypass grafting. METHODS: A short-term decision tree and a long-term Markov model were used to simulate the evolution of patients' life-cycles. Clinical effectiveness data were collected from the PLATO trial and resource use data were obtained from the Hospital de Santa Marta database, disease-related group legislation and the literature. RESULTS: Ticagrelor provides increases of 0.1276 life years and 0.1106 quality-adjusted life years (QALYs) per patient. From a societal perspective these clinical gains entail an increase in expenditure of €610. Thus the incremental cost per life year saved is €4780 and the incremental cost per QALY is €5517. CONCLUSIONS: The simulation results show that ticagrelor reduces events compared to clopidogrel. The costs of ticagrelor are partially offset by lower costs arising from events prevented. The use of ticagrelor in clinical practice is therefore cost-effective compared to generic clopidogrel.